You are on page 1of 1

POTASSIUM-SPARING DIURETICS

Drug Name Clinical Use Phacmacodynamics Toxicity


Mineralocorticoid
receptor antagonist
Spironolactone --Primary aldosteronism (Conn’s -reduce Na + absorption in the collecting  Hyperkalemia
syndrome, tubules and ducts.  Hyperchloremic Metabolic Acidosis
ectopic adrenocorticotropic -Potassium absorption (and K + secretion)  Gynecomastia
hormone production) at this site is regulated by aldosterone  Acute Renal Failure
Eplerenone --secondary hyperaldosteronism -Spironolactone and eplerenone bind to  Kidney Stones
(evoked by heart failure, hepatic mineralocorticoid receptors and blunt Contraindications:
cirrhosis, nephrotic syndrome, or aldosterone activity.  Hyperkalemia
other conditions associated with  Chronic renal insufficiency
diminished effective intravascular  Liver diseases—impaired metabolism of
volume). triamterene/spironolactone
 Strong CYP3A4 inhibitors
(Erythromycin, fluconazole, diltiazem
and grapefruit juice) can markedly
increase blood level of eplerenone but
not spironolactone

ENAC Channel blockers

Amiloride -Amiloride and triamterene do not block


aldosterone, but instead directly interfere
with Na + entry through the epithelial Na +
Triamterene
channels (ENaC) in the apical membrane
of the collecting tubule.
-reduce Na + absorption in the collecting
tubules and ducts
-Potassium absorption (and K + secretion)
at this site is regulated by aldosterone

You might also like